DP2: Decision on continued trading restriction on UPCoM

Following Decision No. 216/QD-SGDHN dated April 01, 2024, HNX announces the continued trading restriction of DP2 stock as follows:
- Reason for trading restriction: the audit organization have expressed disclaimer opinion on the Annual Financial Statement 2023;
- Ground for continued trading restriction: The audited Financial Statement of 2023;
- Trading restriction: be traded on Friday weekly;
- Applicable law(s): Points c, Section 1 Article 34 of the Regulations attached to Decision No.34/QD-HDTV dated 16/11/2022 of the Vietnam Exchange.
Within 15 days from the date the stock is under continued trading restriction as prescribed in this Decision, Central Pharmaceutical Joint Stock Company No2 must send a document to the HNX to explain the cause and provide a remedy.

HNX

>   DP2: Notice of stock status (02/04/2024)

>   GGG: Decision on continued trading restriction and Notice of stock status (02/04/2024)

>   SJM: Board Decision (02/04/2024)

>   SBB: Board Decision (02/04/2024)

>   DSC: Annual General Mandate 2024 (02/04/2024)

>   DDM: Explanation on maintaining transaction restrictions (02/04/2024)

>   DM7: Board Resolution (02/04/2024)

>   BAB: 10/04/2024, first trading date of additional shares (02/04/2024)

>   LMC: Board Resolution (02/04/2024)

>   HSP: Annual General Mandate 2024 (02/04/2024)